Lucas Svetlana
Chief Business Officer
Lucas Svetlana has filed 2 SEC Form 4 filings (2 transaction rows) across 2 companies, including SCTX, JSPR, with disclosures dating back to 2025. 2 of those filings fall inside the rolling window. Most recent filing: Jul 28, 2026.
On the most recent filing, Lucas Svetlana is listed as Chief Business Officer at Scribe Therapeutics, Inc. Inside the rolling window, Lucas Svetlana reported 2 open-market purchases totaling $94K in SCTX and JSPR and no open-market sales. The largest disclosed transaction in the window is a purchase of 20,000 JSPR shares on Sep 22, 2025, worth $49K.
Companies traded
Other insiders at SCTX
Insider Buying
$94K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
2
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Lucas Svetlana made?
Lucas Svetlana has filed 2 SEC Form 4 filings (2 transaction rows) across 2 companies, including SCTX, JSPR since 2025.
Which companies does Lucas Svetlana trade?
Lucas Svetlana has filed SEC Form 4 disclosures for 2 companies, including SCTX, JSPR.
When was Lucas Svetlana's most recent SEC Form 4 filing?
Lucas Svetlana's most recent SEC Form 4 filing on Tracefour is dated Jul 28, 2026.
What is Lucas Svetlana's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Lucas Svetlana is listed as Chief Business Officer.
What is Lucas Svetlana's total buy and sell value in the current window?
Inside the rolling retention window, Lucas Svetlana bought $94K and sold $0 based on SEC Form 4 filings.
What was Lucas Svetlana's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 20,000 JSPR shares on 2025-09-22, worth $49K, per SEC Form 4 filings.